(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists- Ocean side Locations for a Family Excursion
- New Year's Eve Live: Nashville's Big Bash: How to watch the star-studded country music special live
- Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- The best ice packs for coolers of 2026, tested and reviewed
- South Korea launches Earth-observation satellite on homegrown Nuri rocket
- German official report: Teen social media ban faces legal hurdles
- Merz: 80% of Syrians in Germany should return in three years
